NCT03921931

Brief Summary

It has been shown that reactions of human retinal photoreceptors to a light stimulus can be measured with custom-made, research prototype optical coherence tomography (OCT) systems. This can be used as a biomarker for the function of the photoreceptors. Due to the high technical demands on the system, however, the technique is currently not available for clinical purposes. In this pilot study a protocol to measure changes in retinal photoreceptor layer thickness before and after light stimulation shall be developed based on a commercial OCT system and newly developed algorithms. Other variables, such as circadian processes shall be investigated as well. After measurements in healthy volunteers, the protocol is planned to be applied in patients with primary open angle glaucoma (POAG) and age-related macular degeneration (AMD) to test for feasibility of the method in these patient groups.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
0mo left

Started Nov 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress99%
Nov 2018May 2026

Study Start

First participant enrolled

November 26, 2018

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 4, 2019

Completed
15 days until next milestone

First Posted

Study publicly available on registry

April 19, 2019

Completed
7.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2026

Last Updated

May 16, 2025

Status Verified

March 1, 2025

Enrollment Period

7.5 years

First QC Date

April 4, 2019

Last Update Submit

May 13, 2025

Conditions

Keywords

light stimulationretinal photoreceptorslight adaptationfunctional optical coherence tomographyoptophysiologyintrinsic optical signals

Outcome Measures

Primary Outcomes (1)

  • Light stimulation

    Optical path length changes between inner segment outer segment junction and retinal pigment epithelium (RPE) will be measured with OCT in 15 healthy volunteers, 10 POAG patients and 10 AMD patients before and after light stimulation

    1 day

Secondary Outcomes (3)

  • Light stimulation of contralateral eye

    1 day

  • Difference in photoreceptor layer thickness over the course of 8 hours

    8 hours

  • En face maps

    1 day

Study Arms (3)

healthy volunteers

EXPERIMENTAL

light stimulation

Other: White light stimulation

primary open angle glaucoma patients

EXPERIMENTAL

light stimulation

Other: White light stimulation

age-related macular degeneration patients

EXPERIMENTAL

light stimulation

Other: White light stimulation

Interventions

Stimulation of the retina with white light

age-related macular degeneration patientshealthy volunteersprimary open angle glaucoma patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • men and women aged over 18 years
  • signed informed consent form
  • ametropia below 3 diopters
  • ability and willingness to follow instructions
  • for healthy volunteers:
  • normal ophthalmologic findings
  • for primary open angle glaucoma patients (POAG):
  • diagnosed POAG
  • MD \<= 10 dB
  • for age-related macular degeneration (AMD):
  • diagnosed dry AMD
  • diagnosed stage II or stage III AMD

You may not qualify if:

  • Presence of any abnormalities preventing reliable measurements
  • Ocular inflammation and ocular disease interfering with the study aims
  • Use of photosensitizing medication (phototoxic drugs, photoallergic drugs) in the 3 months preceding the study
  • Presence of any condition with the possibility of causing photosensitivity, including systemic lupus erythematosus SLE, Porphyria, Vitiligo, Xeroderma Pigmentosum and Albinism
  • Presence of any form of epilepsy
  • Ocular surgery in the 3 months preceding the study
  • Pregnancy, planned pregnancy or lactating
  • Any medical or surgical history, disorder or disease such as acute or chronic severe organic disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Vienna, Department of Clinical Pharmacology

Vienna, Vienna, 1090, Austria

RECRUITING

MeSH Terms

Conditions

Geographic AtrophyGlaucoma, Open-Angle

Condition Hierarchy (Ancestors)

Macular DegenerationRetinal DegenerationRetinal DiseasesEye DiseasesGlaucomaOcular Hypertension

Study Officials

  • Doreen Schmidl, MD,PhD

    Department of Clinical Pharmacology, Medical University of Vienna

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Doreen Schmidl, MD,PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor, MD, PhD

Study Record Dates

First Submitted

April 4, 2019

First Posted

April 19, 2019

Study Start

November 26, 2018

Primary Completion (Estimated)

May 31, 2026

Study Completion (Estimated)

May 31, 2026

Last Updated

May 16, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations